Scarica l'app Stockscreener
72.08
1.21%
-0.88
Dopo l'orario di chiusura:
72.23
0.15
+0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph
Nektar Therapeutics stock hits 52-week high at 77.36 USD - Investing.com
Nektar Therapeutics stock hits 52-week high at 77.36 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighHere's Why - MarketBeat
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com
Wedbush initiates coverage of Nektar Therapeutics (NKTR) with neutral recommendation - MSN
Wedbush Initiates Coverage on Nektar Therapeutics (NKTR) with Ne - GuruFocus
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Wedbush - MarketBeat
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Wedbush initiates Nektar Therapeutics stock with neutral rating By Investing.com - Investing.com Australia
Wedbush initiates Nektar Therapeutics stock with neutral rating - Investing.com
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead - GlobeNewswire
Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target - marketscreener.com
Wedbush Starts Nektar Therapeutics (NKTR) at Neutral - StreetInsider
Nektar Therapeutics Faces High-Stakes AAD Data Test as Sky-High Valuation Leaves Little Room for Error - Bitget
A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting - simplywall.st
Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Nektar Therapeutics stock is trending Tuesday: What's going on? - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
Apogee strengthens case for longer-lasting eczema drug - BioPharma Dive
Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections - statnews.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
2 Healthcare Stocks to Buy Before They Get Bought Out - AOL.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The AI Journal
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm - WFXG
Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Two skin and hair-loss studies from Nektar get oral AAD slots - Stock Titan
NKTR Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Abivax & Nektar Therapeutics: Clinical-Stage Biotech Drug Development in 2026News and Statistics - IndexBox
2 Healthcare Shares to Consider Purchasing Before Potential Buyouts - Bitget
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting - Sahm
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates - Yahoo Finance
B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With 295+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - ChartMill
Nektar Therapeutics jumps on Q4 results - MSN
TD Cowen initiates coverage of Nektar Therapeutics (NKTR) with buy recommendation - MSN
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):